KR102275090B1 - 표적화된 변형된 il-1 패밀리 구성원 - Google Patents

표적화된 변형된 il-1 패밀리 구성원 Download PDF

Info

Publication number
KR102275090B1
KR102275090B1 KR1020167002679A KR20167002679A KR102275090B1 KR 102275090 B1 KR102275090 B1 KR 102275090B1 KR 1020167002679 A KR1020167002679 A KR 1020167002679A KR 20167002679 A KR20167002679 A KR 20167002679A KR 102275090 B1 KR102275090 B1 KR 102275090B1
Authority
KR
South Korea
Prior art keywords
primer
dna
artificial sequence
targeting
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167002679A
Other languages
English (en)
Korean (ko)
Other versions
KR20160108293A (ko
Inventor
잔 타베르니에
사라 젤로
프랑크 필만
질 유제
Original Assignee
브이아이비 브이지더블유
유니버시테이트 젠트
상트르 나쇼날 드 라 르세르쒸 시앙티피끄
상트르 하스피탈리에 레지오날 유니베르시테르 드 몽쁠리에
유니베르시테 드 몽펠리에
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브이아이비 브이지더블유, 유니버시테이트 젠트, 상트르 나쇼날 드 라 르세르쒸 시앙티피끄, 상트르 하스피탈리에 레지오날 유니베르시테르 드 몽쁠리에, 유니베르시테 드 몽펠리에 filed Critical 브이아이비 브이지더블유
Publication of KR20160108293A publication Critical patent/KR20160108293A/ko
Application granted granted Critical
Publication of KR102275090B1 publication Critical patent/KR102275090B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020167002679A 2013-07-19 2014-07-04 표적화된 변형된 il-1 패밀리 구성원 Active KR102275090B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13306047 2013-07-19
EP13306047.5 2013-07-19
PCT/EP2014/064283 WO2015007542A1 (en) 2013-07-19 2014-07-04 Targeted modified il-1 family members

Publications (2)

Publication Number Publication Date
KR20160108293A KR20160108293A (ko) 2016-09-19
KR102275090B1 true KR102275090B1 (ko) 2021-07-09

Family

ID=48874235

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167002679A Active KR102275090B1 (ko) 2013-07-19 2014-07-04 표적화된 변형된 il-1 패밀리 구성원

Country Status (14)

Country Link
US (5) US9932409B2 (https=)
EP (1) EP3022226B1 (https=)
JP (1) JP6475713B2 (https=)
KR (1) KR102275090B1 (https=)
CN (1) CN105612180B (https=)
AU (1) AU2014292377B2 (https=)
BR (1) BR112016001128A2 (https=)
CA (1) CA2918518C (https=)
DK (1) DK3022226T3 (https=)
ES (1) ES2714504T3 (https=)
IL (1) IL243466B (https=)
MX (1) MX370348B (https=)
SG (1) SG11201600167SA (https=)
WO (1) WO2015007542A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7115982B2 (ja) 2015-10-30 2022-08-09 アレタ・バイオセラピューティクス・インコーポレイテッド 癌の治療のための組成物及び方法
KR20180083868A (ko) 2015-10-30 2018-07-23 알레타 바이오쎄라퓨틱스, 인크. 종양 형질도입용 조성물 및 방법
US11702477B2 (en) 2015-11-06 2023-07-18 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
US11001631B2 (en) 2016-02-05 2021-05-11 Orionis Biosciences BV Clec9A binding agents
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
US11248057B2 (en) 2016-03-07 2022-02-15 Vib Vzw CD20 binding single domain antibodies
EP3443001B1 (en) 2016-04-11 2025-04-30 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
WO2017194783A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
CN109563141A (zh) 2016-05-13 2019-04-02 奥里尼斯生物科学公司 对非细胞结构的治疗性靶向
CA3040802A1 (en) 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
EP3577133A1 (en) 2017-02-06 2019-12-11 Orionis Biosciences NV Targeted chimeric proteins and uses thereof
EP3580230B1 (en) 2017-02-07 2026-04-22 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CA3055200A1 (en) * 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Compositions and methods for immunotherapy
CA3066918A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
JP7423511B2 (ja) 2017-08-09 2024-01-29 オリオンズ バイオサイエンス インコーポレイテッド Ｐｄ－１およびｐｄ－ｌ１結合物質
EP3665201A4 (en) 2017-08-09 2021-06-02 Orionis Biosciences, Inc. CD8 BINDERS
US12091463B2 (en) 2017-08-09 2024-09-17 Orionis Biosciences, Inc. Clec9A binding agents comprising a recombinant heavy-chain only antibody (VHH)
CN111527109B (zh) * 2017-12-26 2024-11-01 南京金斯瑞生物科技有限公司 以抗体Fc区为骨架的融合蛋白二聚体及其应用
US20200354424A1 (en) 2018-01-26 2020-11-12 Orionis Biosciences, Inc. Xcr1 binding agents and uses thereof
JP2021513361A (ja) 2018-02-05 2021-05-27 オリオニス バイオサイエンシーズ，インコーポレイテッド 線維芽細胞結合物質およびその使用
WO2020033646A1 (en) 2018-08-08 2020-02-13 Orionis Biosciences, Inc. SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF
US12410225B2 (en) 2018-11-08 2025-09-09 Orionis Biosciences, Inc Modulation of dendritic cell lineages
JP7689079B2 (ja) 2019-03-28 2025-06-05 オリオニス バイオサイエンシズ，インコーポレイテッド 治療用インターフェロンアルファ１タンパク質
CA3133648A1 (en) 2019-03-28 2020-10-01 Orionis Biosciences, Inc. Fibroblast activation protein binding agents and use thereof
CN120590542A (zh) 2019-03-28 2025-09-05 奥里尼斯生物科学股份有限公司 基于clec9a的嵌合蛋白复合物
WO2020257412A1 (en) 2019-06-19 2020-12-24 Orionis Biosciences, Inc. Combination therapy with cd13-targeted chimeric proteins or chimeric protein complexes
EP4178609A4 (en) * 2020-07-07 2024-07-24 Orionis Biosciences, Inc. IMMUNOSTIMULATORY ADJUVANTS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009003145A1 (en) 2007-06-26 2008-12-31 University Of Miami Antibody-endostatin fusion protein and its variants
WO2011029870A1 (en) 2009-09-10 2011-03-17 Cytos Biotechnology Ag Use of interleukin-1 beta mutein conjugates in the treatment of diabetes

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2055445T3 (es) 1989-08-22 1994-08-16 Immunex Corp Proteinas de fusion que comprenden gm-csf e il-3.
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5914254A (en) 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
WO2001029870A1 (en) * 1999-10-21 2001-04-26 Sarnoff Corporation Bi-potential electrode space-saving cathode ray tube
CA2585549A1 (en) 2004-11-18 2006-05-26 Vib Vzw Novel type leptin receptor antagonist
WO2006115800A2 (en) 2005-04-15 2006-11-02 The Regents Of The University Of California Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha
WO2008014612A1 (en) 2006-08-02 2008-02-07 Mcgill University Fusion proteins and methods for modulation of immune response
US11535673B2 (en) 2007-04-05 2022-12-27 President and Fellows of Harvard CoHege Chimeric activators: quantitatively designed protein therapeutics and uses thereof
ES2536772T3 (es) 2007-09-21 2015-05-28 The Regents Of The University Of California El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales
US8334101B2 (en) * 2008-09-26 2012-12-18 University Of Massachusetts Intracellular DNA receptor
JP2012510806A (ja) 2008-12-08 2012-05-17 コンプリクス エン ヴェー 単鎖逆平行コイルドコイルタンパク質
ES2534085T3 (es) * 2009-08-17 2015-04-17 Roche Glycart Ag Inmunoconjugados dirigidos
EP2718457A4 (en) 2011-06-06 2014-12-24 Immungene Inc GENETICALLY MODIFIED FUSION MOLECULES LIGAND TNFSF-ANTIBODY ELEMENT
SG10201603411WA (en) 2011-10-28 2016-07-28 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
CN104245734B (zh) 2012-01-20 2017-09-05 非营利性组织佛兰芒综合大学生物技术研究所 靶向突变体α‑螺旋束细胞因子
ES2800426T3 (es) 2012-03-03 2020-12-30 Immungene Inc Moléculas de fusión anticuerpos-mutante de interferón modificadas

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009003145A1 (en) 2007-06-26 2008-12-31 University Of Miami Antibody-endostatin fusion protein and its variants
WO2011029870A1 (en) 2009-09-10 2011-03-17 Cytos Biotechnology Ag Use of interleukin-1 beta mutein conjugates in the treatment of diabetes

Also Published As

Publication number Publication date
DK3022226T3 (en) 2019-03-25
US20200255545A1 (en) 2020-08-13
JP6475713B2 (ja) 2019-02-27
IL243466A0 (en) 2016-03-31
IL243466B (en) 2019-11-28
US20160152730A1 (en) 2016-06-02
CA2918518C (en) 2022-08-16
US9932409B2 (en) 2018-04-03
CN105612180A (zh) 2016-05-25
MX2016000723A (es) 2016-12-20
US20180186894A1 (en) 2018-07-05
WO2015007542A1 (en) 2015-01-22
US20230235086A1 (en) 2023-07-27
AU2014292377A1 (en) 2016-02-04
EP3022226A1 (en) 2016-05-25
MX370348B (es) 2019-12-10
KR20160108293A (ko) 2016-09-19
CA2918518A1 (en) 2015-01-22
CN105612180B (zh) 2019-11-12
JP2016527221A (ja) 2016-09-08
US20190202934A1 (en) 2019-07-04
ES2714504T3 (es) 2019-05-28
BR112016001128A2 (pt) 2018-01-23
EP3022226B1 (en) 2018-12-05
SG11201600167SA (en) 2016-02-26
AU2014292377B2 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
KR102275090B1 (ko) 표적화된 변형된 il-1 패밀리 구성원
Huang et al. Airway inflammation and IgE production induced by dust mite allergen-specific memory/effector Th2 cell line can be effectively attenuated by IL-35
KR102222615B1 (ko) 신호전달 시스템
CN108948177B (zh) 融合分子与il-15变异体
JP2021035395A (ja) キメラサイトカイン受容体
EP3003350B1 (en) Targeted modulation of macrophages
KR20060052681A (ko) Ｇｉｔｒ 리간드, ｇｉｔｒ 리간드-연관 분자, 항체 및그의 용도
WO2017137759A1 (en) Signalling system
JP2021527047A (ja) 消化管系へのペイロード送達のための、ｂｔｎｌ３／８を標的とする構築物
WO2022190008A1 (en) Protease cleavable prodrugs
JPWO2019177151A1 (ja) 遺伝子改変細胞及びその作製方法
US20230242666A1 (en) Methods and Compositions for the Reduction of Chimeric Antigen Receptor Tonic Signaling
CN102775501B (zh) 用于肿瘤治疗的白细胞介素21(il-21)药物
HK1225048A1 (en) Targeted modified il-1 family members
HK1225048B (en) Targeted modified il-1 family members
TW202600601A (zh) Ｔｒｏｐ２特異性抗原結合蛋白與細胞激素之共軛物
KR20130011056A (ko) 염증표적 수용체 및 염증 질환 치료용 약물 운반체
JP2026510945A (ja) キメラ抗原受容体の長期発現に適応した細胞内シグナル伝達および共刺激ドメイン
TW202448942A (zh) 用針對ｂ細胞成熟抗原（ｂｃｍａ）的嵌合抗原受體治療疾病的組成物及方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160129

Patent event code: PA01051R01D

Comment text: International Patent Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20160818

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190703

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201106

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210405

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210702

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210705

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240620

Start annual number: 4

End annual number: 4